•
Jun 30, 2023
Praxis Q2 2023 Earnings Report
Praxis Precision Medicines reported financial results for the second quarter 2023.
Key Takeaways
Praxis Precision Medicines reported a net loss of $34.3 million for the second quarter of 2023. The company's cash and cash equivalents were $124.3 million as of June 30, 2023, expected to support runway into Q1 2025.
On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA.
PRAX-628 Phase 1 study showed consistent safety profile and target engagement in measures of qEEG activity at all doses with first administration.
Praxis will hold an R&D Portfolio Day on October 2.
Cash of $124.3 million as of June 30, 2023 expected to support runway into Q1 2025.